Daniel Char - 30 Nov 2022 Form 4 Insider Report for ImmunoGen, Inc.

Role
SVP & CHIEF LEGAL OFFICER
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Nov 2022
Net transactions value
+$2,076,000
Form type
4
Filing time
30 Nov 2022, 16:16:17 UTC
Previous filing
30 Nov 2022
Next filing
05 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Award $2,076,000 +400,000 $5.19 400,000 30 Nov 2022 Common Stock 400,000 $5.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.